Tag: #pharma

FDA Expands IBRANCE Approval for Maintenance Treatment in HR+, HER2+ Metastatic Breast Cancer

FDA expands use of Pfizer’s IBRANCE (palbociclib) as maintenance therapy with trastuzumab and endocrine therapy for HR+, HER2+ metastatic breast cancer.

$PFE, #oncology, #breastcancer, #fda, #pharma

Pfizer Keeps 2026 Outlook as Q1 Revenue Rises 5%; COVID Sales Slide

Pfizer posted 5% revenue growth in Q1 and kept its 2026 outlook, as gains from newer drugs offset steep declines in Comirnaty and Paxlovid sales.

$PFE, #pfizer, #earnings, #pharma